William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating and {REMOVEPT} price target on Apellis Pharmaceuticals (NASDAQ: APLS)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE